Combination Therapy Shows Significant Spleen Volume Reduction in Myelofibrosis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 14 2026
0mins
Source: Yahoo Finance
- Clinical Trial Results: The SENTRY trial demonstrated that the combination of selinexor and ruxolitinib achieved a spleen volume reduction rate (SVR35) of 49.8% at week 24, significantly higher than the control group's 28%, indicating substantial clinical efficacy in myelofibrosis patients.
- Survival Signal: Although the data is immature, preliminary analysis suggests that the selinexor combination therapy reduces the risk of death by over 50% (HR 0.43) compared to ruxolitinib alone, providing potential survival benefits for patients, which is clinically significant.
- Symptom Improvement: The combination therapy showed a comparable improvement in Absolute Total Symptom Score (Abs-TSS) to ruxolitinib alone, although the difference was not statistically significant, indicating the combination's potential in symptom management.
- Safety and Tolerability: The combination demonstrated a manageable safety and tolerability profile consistent with the known characteristics of selinexor and ruxolitinib individually, with no new safety signals observed, enhancing its clinical applicability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KPTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KPTI
Wall Street analysts forecast KPTI stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 9.400
Low
6.00
Averages
13.83
High
21.00
Current: 9.400
Low
6.00
Averages
13.83
High
21.00
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer. It is developing and commercializing novel, small molecule XPO1 inhibitor compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO is also marketed for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including myelofibrosis, endometrial cancer and multiple myeloma. The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Combination Therapy Shows Significant Spleen Volume Reduction in Myelofibrosis
- Clinical Trial Results: The SENTRY trial demonstrated that the combination of selinexor and ruxolitinib achieved a spleen volume reduction rate (SVR35) of 49.8% at week 24, significantly higher than the control group's 28%, indicating substantial clinical efficacy in myelofibrosis patients.
- Survival Signal: Although the data is immature, preliminary analysis suggests that the selinexor combination therapy reduces the risk of death by over 50% (HR 0.43) compared to ruxolitinib alone, providing potential survival benefits for patients, which is clinically significant.
- Symptom Improvement: The combination therapy showed a comparable improvement in Absolute Total Symptom Score (Abs-TSS) to ruxolitinib alone, although the difference was not statistically significant, indicating the combination's potential in symptom management.
- Safety and Tolerability: The combination demonstrated a manageable safety and tolerability profile consistent with the known characteristics of selinexor and ruxolitinib individually, with no new safety signals observed, enhancing its clinical applicability.
See More
Karyopharm to Participate in Virtual Fireside Chat
- Virtual Meeting Announcement: Karyopharm Therapeutics will participate in a virtual fireside chat hosted by Cantor on June 8, 2026, at 12:00 PM ET, featuring the company's senior management team and renowned gynecologic oncologist Dr. Robert Coleman, aimed at showcasing the company's latest developments to institutional investors.
- XPOVIO Treatment Progress: Karyopharm's lead therapy, XPOVIO (selinexor), is the first export inhibitor approved in the U.S. for relapsed or refractory multiple myeloma and has been approved in over 50 countries, demonstrating its broad market potential globally.
- Clinical Trial Updates: The company is advancing XPOVIO's applications in hematologic and solid tumors, including myelofibrosis and TP53 wild-type endometrial cancer, indicating Karyopharm's ongoing innovation and research capabilities in cancer treatment.
- Commercial Infrastructure: Headquartered in Newton, Massachusetts, Karyopharm has an efficient and scalable commercial infrastructure designed to provide novel therapeutic options for cancer patients, further solidifying its leadership position in the biopharmaceutical industry.
See More
Karyopharm to Participate in Virtual Investor Fireside Chat
- Virtual Meeting Announcement: Karyopharm Therapeutics will participate in a virtual investor fireside chat hosted by Cantor on June 8, 2026, at 12:00 p.m. ET, featuring the company's senior management team and renowned gynecologic oncologist Dr. Robert Coleman, aiming to engage institutional investors.
- XPOVIO Drug Overview: Karyopharm's lead therapy, XPOVIO (selinexor), is the first-in-class exportin 1 inhibitor approved in the U.S. for relapsed or refractory multiple myeloma, with approvals in over 50 countries, highlighting its significant global market potential.
- Clinical Trial Developments: The company is advancing XPOVIO's applications in hematologic and solid tumors, including evaluations for myelofibrosis and TP53 wild-type endometrial cancer, indicating its ongoing innovation in cancer treatment.
- Commercial Infrastructure: Headquartered in Newton, Massachusetts, Karyopharm has established an efficient and scalable commercial infrastructure to deliver novel therapeutic options to cancer patients, further solidifying its leadership position in the oncology market.
See More
Karyopharm's SENTRY Trial Data to be Presented at EHA Congress
- Clinical Trial Results: Karyopharm's new data from the SENTRY trial will be presented at the 2026 European Hematology Association Congress, showcasing the significant effects of selinexor combined with ruxolitinib on spleen volume reduction, which may predict improved overall survival for patients.
- Key Data Analysis: New findings indicate that achieving a 35% spleen volume reduction (SVR35) in the Phase 1 portion of the SENTRY trial may correlate with better survival outcomes, further supporting the clinical application potential of this combination therapy.
- Innovative Mechanism of Action: As the first-in-class exportin inhibitor, selinexor demonstrates a distinct mechanism of action compared to JAK inhibitors, potentially offering new treatment options for myelofibrosis patients and addressing the urgent market need for novel therapies.
- Broad Market Potential: Karyopharm's research shows that the combination of selinexor and ruxolitinib nearly doubles the proportion of patients achieving SVR35 by week 12, indicating strong competitive positioning and potential economic benefits in the future market.
See More
Karyopharm Presents SENTRY Trial Results at EHA Congress
- Clinical Trial Results: Karyopharm's SENTRY trial results indicate that the combination of selinexor and ruxolitinib can achieve a 35% spleen volume reduction (SVR35), which may predict overall survival for patients, highlighting the significant potential of this combination in treating myelofibrosis.
- EHA Congress Recognition: This study has been selected as one of the six best abstracts by the European Hematology Association (EHA) Scientific Program Committee, and will be presented orally on June 14, 2026, in Stockholm, enhancing Karyopharm's reputation in the academic community.
- Patient Benefits: The research shows that the combination of selinexor and ruxolitinib nearly doubles the proportion of patients achieving SVR35 by week 12, demonstrating the potential of this treatment regimen to improve patient symptoms and extend survival, addressing the urgent need for new therapies.
- Future Outlook: Karyopharm plans to continue advancing selinexor's applications in various cancers, particularly in myelofibrosis and TP53 wild-type endometrial cancer, showcasing the company's strategic positioning in the field of innovative therapies.
See More
Karyopharm Grants Restricted Stock Units to New Employee
- Employee Incentive Plan: Karyopharm Therapeutics granted 1,200 restricted stock units (RSUs) to a newly hired employee on May 31, 2026, as part of its strategy to attract and retain talent, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Schedule: The RSU award will vest over three years, with 33 1/3% of the shares vesting annually, ensuring the employee's continued contribution to the company, thereby enhancing loyalty and motivation among staff.
- Company Overview: Karyopharm is a commercial-stage pharmaceutical company focused on developing cancer therapies, with its lead product XPOVIO® being the first export inhibitor approved in the U.S. and over 50 countries, showcasing its innovative capabilities in cancer treatment.
- Future Development Potential: Karyopharm is exploring the application of XPO1 inhibition in various cancers, including myelofibrosis and TP53 wild-type endometrial cancer, indicating the company's commitment to advancing cancer treatment through next-generation compounds.
See More
Combination Therapy Shows Significant Spleen Volume Reduction in Myelofibrosis
- Clinical Trial Results: The SENTRY trial demonstrated that the combination of selinexor and ruxolitinib achieved a spleen volume reduction rate (SVR35) of 49.8% at week 24, significantly higher than the control group's 28%, indicating substantial clinical efficacy in myelofibrosis patients.
- Survival Signal: Although the data is immature, preliminary analysis suggests that the selinexor combination therapy reduces the risk of death by over 50% (HR 0.43) compared to ruxolitinib alone, providing potential survival benefits for patients, which is clinically significant.
- Symptom Improvement: The combination therapy showed a comparable improvement in Absolute Total Symptom Score (Abs-TSS) to ruxolitinib alone, although the difference was not statistically significant, indicating the combination's potential in symptom management.
- Safety and Tolerability: The combination demonstrated a manageable safety and tolerability profile consistent with the known characteristics of selinexor and ruxolitinib individually, with no new safety signals observed, enhancing its clinical applicability.
See More
Karyopharm to Participate in Virtual Fireside Chat
- Virtual Meeting Announcement: Karyopharm Therapeutics will participate in a virtual fireside chat hosted by Cantor on June 8, 2026, at 12:00 PM ET, featuring the company's senior management team and renowned gynecologic oncologist Dr. Robert Coleman, aimed at showcasing the company's latest developments to institutional investors.
- XPOVIO Treatment Progress: Karyopharm's lead therapy, XPOVIO (selinexor), is the first export inhibitor approved in the U.S. for relapsed or refractory multiple myeloma and has been approved in over 50 countries, demonstrating its broad market potential globally.
- Clinical Trial Updates: The company is advancing XPOVIO's applications in hematologic and solid tumors, including myelofibrosis and TP53 wild-type endometrial cancer, indicating Karyopharm's ongoing innovation and research capabilities in cancer treatment.
- Commercial Infrastructure: Headquartered in Newton, Massachusetts, Karyopharm has an efficient and scalable commercial infrastructure designed to provide novel therapeutic options for cancer patients, further solidifying its leadership position in the biopharmaceutical industry.
See More
Karyopharm to Participate in Virtual Investor Fireside Chat
- Virtual Meeting Announcement: Karyopharm Therapeutics will participate in a virtual investor fireside chat hosted by Cantor on June 8, 2026, at 12:00 p.m. ET, featuring the company's senior management team and renowned gynecologic oncologist Dr. Robert Coleman, aiming to engage institutional investors.
- XPOVIO Drug Overview: Karyopharm's lead therapy, XPOVIO (selinexor), is the first-in-class exportin 1 inhibitor approved in the U.S. for relapsed or refractory multiple myeloma, with approvals in over 50 countries, highlighting its significant global market potential.
- Clinical Trial Developments: The company is advancing XPOVIO's applications in hematologic and solid tumors, including evaluations for myelofibrosis and TP53 wild-type endometrial cancer, indicating its ongoing innovation in cancer treatment.
- Commercial Infrastructure: Headquartered in Newton, Massachusetts, Karyopharm has established an efficient and scalable commercial infrastructure to deliver novel therapeutic options to cancer patients, further solidifying its leadership position in the oncology market.
See More
Karyopharm's SENTRY Trial Data to be Presented at EHA Congress
- Clinical Trial Results: Karyopharm's new data from the SENTRY trial will be presented at the 2026 European Hematology Association Congress, showcasing the significant effects of selinexor combined with ruxolitinib on spleen volume reduction, which may predict improved overall survival for patients.
- Key Data Analysis: New findings indicate that achieving a 35% spleen volume reduction (SVR35) in the Phase 1 portion of the SENTRY trial may correlate with better survival outcomes, further supporting the clinical application potential of this combination therapy.
- Innovative Mechanism of Action: As the first-in-class exportin inhibitor, selinexor demonstrates a distinct mechanism of action compared to JAK inhibitors, potentially offering new treatment options for myelofibrosis patients and addressing the urgent market need for novel therapies.
- Broad Market Potential: Karyopharm's research shows that the combination of selinexor and ruxolitinib nearly doubles the proportion of patients achieving SVR35 by week 12, indicating strong competitive positioning and potential economic benefits in the future market.
See More
Karyopharm Presents SENTRY Trial Results at EHA Congress
- Clinical Trial Results: Karyopharm's SENTRY trial results indicate that the combination of selinexor and ruxolitinib can achieve a 35% spleen volume reduction (SVR35), which may predict overall survival for patients, highlighting the significant potential of this combination in treating myelofibrosis.
- EHA Congress Recognition: This study has been selected as one of the six best abstracts by the European Hematology Association (EHA) Scientific Program Committee, and will be presented orally on June 14, 2026, in Stockholm, enhancing Karyopharm's reputation in the academic community.
- Patient Benefits: The research shows that the combination of selinexor and ruxolitinib nearly doubles the proportion of patients achieving SVR35 by week 12, demonstrating the potential of this treatment regimen to improve patient symptoms and extend survival, addressing the urgent need for new therapies.
- Future Outlook: Karyopharm plans to continue advancing selinexor's applications in various cancers, particularly in myelofibrosis and TP53 wild-type endometrial cancer, showcasing the company's strategic positioning in the field of innovative therapies.
See More
Karyopharm Grants Restricted Stock Units to New Employee
- Employee Incentive Plan: Karyopharm Therapeutics granted 1,200 restricted stock units (RSUs) to a newly hired employee on May 31, 2026, as part of its strategy to attract and retain talent, in compliance with Nasdaq Listing Rule 5635(c)(4).
- Vesting Schedule: The RSU award will vest over three years, with 33 1/3% of the shares vesting annually, ensuring the employee's continued contribution to the company, thereby enhancing loyalty and motivation among staff.
- Company Overview: Karyopharm is a commercial-stage pharmaceutical company focused on developing cancer therapies, with its lead product XPOVIO® being the first export inhibitor approved in the U.S. and over 50 countries, showcasing its innovative capabilities in cancer treatment.
- Future Development Potential: Karyopharm is exploring the application of XPO1 inhibition in various cancers, including myelofibrosis and TP53 wild-type endometrial cancer, indicating the company's commitment to advancing cancer treatment through next-generation compounds.
See More
